RSS0393 Phase 3 Psoriasis Trial Registered
ClinicalTrials.gov Studies
Summary
The NIH ClinicalTrials.gov registry has posted a Phase 3 clinical study (NCT07543224) evaluating RSS0393 ointment in adult patients with plaque psoriasis. The multicenter, randomized, double-blind, placebo-controlled trial will assess efficacy and safety of RSS0393 ointment 0.03% versus placebo. No regulatory compliance obligations or action items are associated with this trial registration.
What changed
The NIH ClinicalTrials.gov registry has added a new Phase 3 clinical trial entry for RSS0393 ointment as a potential treatment for plaque psoriasis. The trial is described as multicenter, randomized, double-blind, and placebo-controlled, studying the 0.03% formulation against placebo in adult patients.
This registry entry is informational only and does not impose compliance obligations on sponsors, investigators, or other parties. Pharmaceutical companies and clinical research organizations conducting similar dermatology trials may note this competitive entry in the psoriasis treatment pipeline, but no regulatory response is required.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.
Phase 3 NCT07543224 Kind: PHASE3 Apr 21, 2026
Abstract
Phase III Efficacy and Safety Study of RSS0393 Ointment in Plaque Psoriasis.
Conditions: Plaque Psoriasis Subjects
Interventions: RSS0393 ointment 0.03%, RSS0393 ointment placebo
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.